Remdesivir ndi mankhwala oletsa ma virus omwe amalimbana ndi ma virus osiyanasiyana. Anapangidwa zaka khumi zapitazo kuti athetse matenda a chiwindi C ndi kachilombo kozizira kotchedwa kupuma syncytial virus (RSV). Remdesivir sanali mankhwala othandiza pa matenda onsewa. Koma zidawonetsa kulonjeza motsutsana ndi ma virus ena.

Ofufuza adayesa remdesivir m'mayesero azachipatala panthawi ya Ebola. Mankhwala ena ofufuza adagwira ntchito bwino, koma adawonetsedwa kuti ndi otetezeka kwa odwala. Kafukufuku wama cell ndi nyama adawonetsa kuti remdesivir inali yothandiza polimbana ndi ma virus a m'banja la coronavirus, monga Middle East Respiratory Syndrome (MERS) ndi Severe Acute Respiratory Syndrome (SARS).

Remdesivir imagwira ntchito posokoneza kupanga kachilomboka. Ma Coronaviruses ali ndi ma genome opangidwa ndi ribonucleic acid (RNA). Remdesivir imasokoneza imodzi mwama enzymes ofunikira omwe kachilomboka kamayenera kutengera RNA. Izi zimalepheretsa kachilomboka kuti zisachuluke.

Ofufuza adayamba kuyesa mwachisawawa, koyendetsedwa ndi antiviral mu February 2020 kuyesa ngati remdesivir ingagwiritsidwe ntchito pochiza SARS-CoV-2, coronavirus yomwe imayambitsa COVID-19. Pofika mwezi wa April,zotsatira zoyambiriraadawonetsa kuti remdesivir idafulumizitsa kuchira kwa odwala omwe ali m'chipatala omwe ali ndi COVID-19. Anakhala mankhwala oyamba kulandira chilolezo chogwiritsa ntchito mwadzidzidzi kuchokera ku US Food and Drug Administration (FDA) kuchiza anthu omwe ali m'chipatala ndi COVID-19.

Ofufuza tsopano amaliza kuyesako, komwe kumadziwika kuti Adaptive COVID-19 Treatment Trial (ACTT-1). Kafukufukuyu adathandizidwa ndi National Institute of Allergy and Infectious Diseases (NIAID). Lipoti lomaliza linawonekera muNew England Journal of Medicinepa Okutobala 8, 2020.